Dyadic International has appointed Joe Hazelton as President, effective immediately, as part of its ongoing strategic transformation to become a revenue-generating provider of ancillary recombinant protein products. The biotechnology company's Board of Directors endorsed this leadership change to accelerate execution of its pivot toward high-growth markets including life sciences, nutrition, and industrial applications.
Strategic Pivot Gains Commercial Validation
Over the past 18 months, Dyadic has deliberately shifted focus to prioritize near-term commercialization opportunities in high-value segments such as cell culture media, DNA/RNA technologies, and non-animal food and nutrition ingredients. This strategic pivot has achieved commercial validation through several high-value transactions in the ancillary protein space.
Key partnerships include a develop-and-commercialize partnership with Proliant Health and Biologicals for recombinant human albumin, a collaboration with a non-animal dairy enzyme company, and a joint venture with Fermbox Bio that led to the launch of EN3ZYME. The EN3ZYME launch recently resulted in a significant purchase order in the cellulosic enzyme market.
"We believe the achievement of these milestones validates our strategy and reflects the growing demand for ancillary recombinant proteins," said Mark Emalfarb, Dyadic's Founder and Chief Executive Officer. "We previously communicated an initial focus in the ancillary protein space, we have successfully executed on key initial agreements, and now we are reaffirming that focus by aligning our leadership team to accelerate growth."
Leadership Realignment for Growth Acceleration
As President, Joe Hazelton will be responsible for scaling Dyadic's scientific and commercial initiatives, deepening industry partnerships, overseeing daily operations, and ensuring efficient execution of the business strategy. He will also guide the company's corporate rebranding efforts in support of this strategic shift.
"We see this as a pivotal moment for Dyadic," said Joe Hazelton, who will continue serving as Chief Operating Officer alongside his new presidential role. "We've proven the commercial readiness of our platforms with valuable partnerships and revenue. Now we're aligning our organization to scale and expand across the life sciences, food, and nutrition markets."
Hazelton joined Dyadic in 2021 as Chief Business Officer and was promoted to Chief Operating Officer in 2024. His experience includes over two decades of leadership in biotech commercialization, with a proven track record of strategic execution at both Dyadic and Novartis.
Platform Technologies Drive Commercial Success
Dyadic's C1 and Dapibus™ platforms remain central to the company's recent commercial successes and continue to underpin its strategy. These platforms offer differentiated, large-scale, high-titer production of recombinant proteins across targeted non-therapeutic markets.
The company's microbial gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). The C1-cell protein production platform is based on an industrially proven microorganism currently used to speed development, lower production costs, and potentially improve performance of biologic vaccines and drugs at flexible commercial scales.
The Dapibus™ protein production platform enables rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for non-pharmaceutical applications including food, nutrition, and wellness.
Geopolitical Positioning and Future Focus
Dyadic is positioned to capitalize on geopolitical tailwinds driving reshoring and friendshoring of biomanufacturing supply chains to the United States and allied countries. While the significant majority of the company's focus will be on the ancillary protein opportunity, legacy biopharmaceutical programs remain active under Emalfarb's oversight, who will continue as Chief Executive Officer and Board member while focusing on funding opportunities, IP strategy, and legacy projects.
